Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.<\/p>\n\n\n\n
Date: January 21, 2022, time: 05:08 p.m.<\/p>\n\n\n\n
The Management Board of Celon Pharma S.A. (“Company”) announces that on January 21, 2022, it learned about the inclusion of the first patient in the Phase II clinical trial of CPL’280, a second-generation GPR40 receptor agonist.<\/p>\n\n\n\n
This study is aimed at assessing the effectiveness of the compound as a glucose-lowering antidiabetic drug in a group of approximately 90 patients. Patient recruitment for the study will take 4-5 months.<\/p>\n\n\n\n
CPL’280 is a representative of the latest generation of GPR40 agonists used in diabetes and metabolic diseases. The compound has previously demonstrated an exceptionally favorable safety profile in preclinical and phase I trials, which distinguishes it from other drugs in its class.<\/p>\n\n\n\n
Clinical development of CPL’280 is carried out as part of the GATE project, for which the Company received funding from the National Center for Research and Development (POIR), in the amount of PLN 24.7 million.<\/p>\n","protected":false},"excerpt":{"rendered":"